Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
Last trade$27.52
Day change-$0.405 (-1.45%)
Day range$27.30 – $28.28
Volume298,293
Market cap$1.61B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.61B
Price / earnings
—
Price / book
1.08×
Price / sales
0.7×
EV / sales
1.24×
EV / EBITDA
8.53×
Profitability
Earnings per share
-$9.14
Return on assets
-14.12%
Return on equity
-35.32%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.84×
Current ratio
2.15×
Quick ratio
1.08×
Cash ratio
0.02×
Cash flow
Price / cash flow
6.22×
Price / free cash flow
23.16×
Free cash flow
$69.56M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ENOV, quarterly periods
Line item
Q3 FY2026 Oct 2, 2026
Q2 FY2026 Jul 3, 2026
Q1 FY2026 Apr 3, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Oct 3, 2025
Q2 FY2025 Jul 4, 2025
Q1 FY2025 Apr 4, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$558.73M
$582.78M
$589.15M
$575.76M
$548.91M
$564.55M
$558.83M
$560.98M
Cost of revenue
$218.88M
$223.53M
$223.67M
$226.34M
$220M
$229.85M
$226.61M
$253.46M
Gross profit
$339.85M
$359.25M
$365.49M
$349.42M
$328.91M
$334.7M
$332.23M
$307.52M
Selling, general and administrative
$259.38M
$263.73M
$282.81M
$270.44M
$263.62M
$267.07M
$269.02M
$257.71M
Research and development
$31.28M
$31.69M
$31.53M
$31.37M
$29.74M
$30.7M
$28.53M
$23.95M
Total operating expenses
$336.47M
$341.84M
$358.96M
$851.6M
$887.4M
$351.49M
$379M
$972.27M
Operating income
$3.38M
$17.41M
$6.53M
-$502.18M
-$558.49M
-$16.8M
-$46.77M
-$664.75M
Interest expense
-$7.62M
-$8.04M
-$9.17M
-$7.51M
-$8.83M
-$9.29M
-$9.19M
-$9.07M
Income before taxes
-$456K
$7.47M
$634K
-$509.55M
-$566.87M
-$25.65M
-$57.35M
-$673.73M
Income taxes
-$1.68M
$8.5M
$9.05M
$9.26M
$4.01M
$10.8M
-$1.77M
$29.9M
Net income
$3.42M
-$1.04M
-$8.45M
-$520.45M
-$570.91M
-$36.55M
-$55.71M
-$703.2M
Net income attributable to common shareholders
$3.14M
-$1.19M
-$8.76M
-$520.59M
-$571.15M
-$36.74M
-$55.97M
-$703.34M
EBITDA
$79.45M
$93.3M
$82.59M
$79.45M
$66.24M
$55.47M
$28.53M
$59.38M
Basic earnings per share
$0.06
-$0.02
-$0.15
-$9.10
-$9.99
-$0.64
-$0.98
-$12.58
Diluted earnings per share
$0.06
-$0.02
-$0.15
-$9.10
-$9.99
-$0.64
-$0.98
-$12.58
Recent news
Company coverage with links to the original publishers.
Enovis reported Q3 2026 earnings of $0.88 per share, beating consensus estimates of $0.76 by 15.79%, with revenues of $558.73 million slightly exceeding expectations. However, the stock has underperformed the S&P 500 by 20.6% year-to-date. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. Carlsmed is expected to report results on November 10 with an anticipated quarterly loss of $0.42 per share.
Enovis Corporation (NYSE: ENOV) announced it will host an investor conference call on August 6th, 2026 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results. The company will issue an earnings press release that morning, with the live webcast and presentation accessible from its website.
The article highlights four undervalued growth stocks positioned to benefit from long-term secular trends: Enovis (orthopedic implants driven by aging population), Insteel Industries (infrastructure and data center construction), Mueller Water Products (water infrastructure replacement), and Proto Labs (transitioning from prototyping to production manufacturing). All trade under $100 and are recommended for patient, long-term investors.
Front Street Capital Management purchased 384,124 additional shares of Enovis (ENOV) in Q1 2026 for approximately $9.08 million, increasing their stake to 2.25% of fund assets. The purchase signals institutional confidence in the medical device company despite ENOV shares being down 23.99% over the past year. Insider buying activity also suggests bullish sentiment, though the company reported a net loss of $1.14 billion in trailing twelve months.
Enovis Corporation (NYSE: ENOV) announced it will host an investor conference call on May 7th, 2026 at 8:30 a.m. ET to discuss first quarter 2026 financial results. The company reported continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically, with Reconstructive sales growing 10% year-over-year on a reported basis and 8% organically.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.